AYA.AX Artrya (ASX) closed A$4.15 23 Jan 2026: AI diagnostics could lift value
AYA.AX stock closed at A$4.15 on the ASX on 23 Jan 2026 after a 3.49% intraday rise, signalling renewed investor interest in Artrya Limited’s AI-driven cardiac imaging. The move followed a bounce from the day low of A$3.87 and sits below the 52-week high of A$5.24. Trading volume was 342,272 shares, below the 50-day average of 871,023, showing selective buying. We examine financials, technicals, Meyka forecasts, and the AI growth case that could shape the stock’s near-term outlook.
AYA.AX stock: Price action and quick facts
Artrya Limited (AYA.AX) closed at A$4.15 on the ASX in Australia on 23 Jan 2026. Market cap is A$470,278,000.00 and shares outstanding are 113,320,000. The stock opened at A$4.00, hit a low of A$3.87, and a high of A$4.15. Year range is A$0.56–A$5.24. These figures link short-term momentum to the company’s AI product adoption and upcoming earnings calendar.
Financials, valuation and AYA.AX earnings context
Artrya reports negative earnings per share of -A$0.18 and a trailing PE of -23.06, reflecting current losses. Key ratios show a current ratio of 8.27 and cash per share of A$0.11, which point to short-term liquidity. Price-to-book sits at 20.09, and price-to-sales is exceptionally high at 16,795.64, highlighting early-stage revenue. Recent financial growth shows gross profit decline and stretched operating cash flow, so AYA.AX earnings must improve to justify higher valuation.
Technicals and trading signals for AYA.AX stock
Momentum indicators are mixed. The RSI reads 70.89, which is in overbought territory. MACD is positive with MACD 0.40 and signal 0.32, and ADX at 40.86 shows a strong trend. Bollinger Bands place the middle at A$4.20 and lower band at A$3.23, suggesting current price is near resistance. Average volume is 871,023, while today’s volume was 342,272, implying price moves on lighter liquidity. Traders should watch a break above A$4.20–A$4.30 for continuation.
Meyka AI grade and AYA.AX analysis
Meyka AI rates AYA.AX with a score out of 100: 59.17, Grade C+, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score reflects strong AI market potential but mixed financial metrics. These grades are not guaranteed and we are not financial advisors.
Forecasts, price targets and risk-reward for AYA.AX forecast
Meyka AI’s forecast model projects a 12-month price of A$7.30, a quarterly target of A$6.10, and a monthly level near A$4.06. Compared with the current A$4.15, the 12-month projection implies upside of 75.96%. We show a conservative analyst-style price target range: base A$5.00, upside A$7.30, downside risk A$2.00. Forecasts are model-based projections and not guarantees.
Sector context and catalysts for AYA.AX stock opportunities
Artrya sits in Healthcare, Medical – Healthcare Information Services, where average sector PE is 33.86. The AI diagnostics niche can command premium multiples when revenue scales. Catalysts include contract wins for Salix, regulatory clearances, and stronger recurring revenue. Risks include slow adoption, thin trading liquidity, and negative EPS trends. For more market context see coverage at Investing.com and broader listings at Markets Insider. For company details visit the Artrya page on Meyka: Artrya AYA.AX on Meyka.
Final Thoughts
Key takeaways: AYA.AX stock closed at A$4.15 on 23 Jan 2026 with a 3.49% daily gain on lighter volume. The company’s AI-based Salix platform gives a clear growth narrative but current financials show negative EPS -A$0.18, high price-to-book 20.09, and stretched valuation metrics. Meyka AI’s forecast model projects a 12-month target of A$7.30, implying upside of 75.96% versus today’s price; forecasts are model-based projections and not guarantees. Our grade, C+ / HOLD, balances AI opportunity against execution and revenue risks. Investors should watch upcoming earnings on 2026-02-24, adoption milestones, and quarterly revenue growth. Use position sizing and monitor liquidity before adding AYA.AX to a portfolio. Meyka AI provided the AI-powered market analysis in this report.
FAQs
What drove AYA.AX stock higher today?
AYA.AX stock rose to A$4.15 on 23 Jan 2026 after intraday buying near the A$3.87 low. The move reflected renewed interest in Artrya’s AI diagnostics and technical momentum, not a major company announcement.
What is Meyka AI’s price forecast for AYA.AX stock?
Meyka AI’s forecast model projects A$7.30 for AYA.AX stock in 12 months, implying 75.96% upside from A$4.15. Forecasts are model-based projections and not guarantees.
Is AYA.AX a buy, hold or sell?
Meyka AI rates AYA.AX C+ with a HOLD suggestion. The grade balances the AI growth case against negative EPS, high valuation, and adoption risk. This is informational, not financial advice.
When is Artrya’s next earnings report?
Artrya’s next earnings announcement is scheduled for 2026-02-24. Investors should watch revenue trends and any commentary on Salix adoption and recurring revenue.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
